Erin L Abner1, Richard J Kryscio2, Frederick A Schmitt3, David W Fardo2, Daniela C Moga4, Eseosa T Ighodaro5, Gregory A Jicha3, Lei Yu6, Hiroko H Dodge7, Chengjie Xiong8, Randall L Woltjer9, Julie A Schneider10, Nigel J Cairns11, David A Bennett6, Peter T Nelson12. 1. Department of Epidemiology, University of Kentucky, Lexington, KY. 2. Department of Biostatistics, University of Kentucky, Lexington, KY. 3. Department of Neurology, University of Kentucky, Lexington, KY. 4. Department of Pharmacy Practice and Science, University of Kentucky, Lexington, KY. 5. Department of Anatomy and Neurobiology, University of Kentucky, Lexington, KY. 6. Department of Neurological Sciences, Rush University Medical Center, Chicago, IL. 7. Department of Neurology, Oregon Health & Science University, Portland, OR. 8. Division of Biostatistics, Washington University, St Louis, MO. 9. Department of Pathology, Oregon Health & Science University, Portland, OR. 10. Department of Pathology, Rush University Medical Center, Chicago, IL. 11. Department of Neurology, Washington University, St Louis, MO. 12. Department of Pathology, University of Kentucky, Lexington, KY.
Abstract
OBJECTIVE: To determine clinical and neuropathological outcomes following a clinical diagnosis of mild cognitive impairment (MCI). METHODS: Data were drawn from a large autopsy series (N = 1,337) of individuals followed longitudinally from normal or MCI status to death, derived from 4 Alzheimer Disease (AD) Centers in the United States. RESULTS: Mean follow-up was 7.9 years. Of the 874 individuals ever diagnosed with MCI, final clinical diagnoses were varied: 39.2% died with an MCI diagnosis, 46.8% with a dementia diagnosis, and 13.9% with a diagnosis of intact cognition. The latter group had pathological features resembling those with a final clinical diagnosis of MCI. In terms of non-AD pathologies, both primary age-related tauopathy (p < 0.05) and brain arteriolosclerosis pathology (p < 0.001) were more severe in MCI than cognitively intact controls. Among the group that remained MCI until death, mixed AD neuropathologic changes (ADNC; ≥1 comorbid pathology) were more frequent than "pure" ADNC pathology (55% vs 22%); suspected non-Alzheimer pathology comprised the remaining 22% of cases. A majority (74%) of subjects who died with MCI were without "high"-level ADNC, Lewy body disease, or hippocampal sclerosis pathologies; this group was enriched in cerebrovascular pathologies. Subjects who died with dementia and were without severe neurodegenerative pathologies tended to have cerebrovascular pathology and carry the MCI diagnosis for a longer interval. INTERPRETATION: MCI diagnosis usually was associated with comorbid neuropathologies; less than one-quarter of MCI cases showed "pure" AD at autopsy. Ann Neurol 2017;81:549-559.
OBJECTIVE: To determine clinical and neuropathological outcomes following a clinical diagnosis of mild cognitive impairment (MCI). METHODS: Data were drawn from a large autopsy series (N = 1,337) of individuals followed longitudinally from normal or MCI status to death, derived from 4 Alzheimer Disease (AD) Centers in the United States. RESULTS: Mean follow-up was 7.9 years. Of the 874 individuals ever diagnosed with MCI, final clinical diagnoses were varied: 39.2% died with an MCI diagnosis, 46.8% with a dementia diagnosis, and 13.9% with a diagnosis of intact cognition. The latter group had pathological features resembling those with a final clinical diagnosis of MCI. In terms of non-AD pathologies, both primary age-related tauopathy (p < 0.05) and brain arteriolosclerosis pathology (p < 0.001) were more severe in MCI than cognitively intact controls. Among the group that remained MCI until death, mixed AD neuropathologic changes (ADNC; ≥1 comorbid pathology) were more frequent than "pure" ADNC pathology (55% vs 22%); suspected non-Alzheimer pathology comprised the remaining 22% of cases. A majority (74%) of subjects who died with MCI were without "high"-level ADNC, Lewy body disease, or hippocampal sclerosis pathologies; this group was enriched in cerebrovascular pathologies. Subjects who died with dementia and were without severe neurodegenerative pathologies tended to have cerebrovascular pathology and carry the MCI diagnosis for a longer interval. INTERPRETATION: MCI diagnosis usually was associated with comorbid neuropathologies; less than one-quarter of MCI cases showed "pure" AD at autopsy. Ann Neurol 2017;81:549-559.
Authors: Stephanie Jb Vos; Chengjie Xiong; Pieter Jelle Visser; Mateusz S Jasielec; Jason Hassenstab; Elizabeth A Grant; Nigel J Cairns; John C Morris; David M Holtzman; Anne M Fagan Journal: Lancet Neurol Date: 2013-09-04 Impact factor: 44.182
Authors: Frederick A Schmitt; Peter T Nelson; Erin Abner; Stephen Scheff; Gregory A Jicha; Charles Smith; Gregory Cooper; Marta Mendiondo; Deborah D Danner; Linda J Van Eldik; Allison Caban-Holt; Mark A Lovell; Richard J Kryscio Journal: Curr Alzheimer Res Date: 2012-07 Impact factor: 3.498
Authors: Sukriti Nag; Lei Yu; Ana W Capuano; Robert S Wilson; Sue E Leurgans; David A Bennett; Julie A Schneider Journal: Ann Neurol Date: 2015-04-22 Impact factor: 10.422
Authors: David S Knopman; Clifford R Jack; Heather J Wiste; Stephen D Weigand; Prashanthi Vemuri; Val J Lowe; Kejal Kantarci; Jeffrey L Gunter; Matthew L Senjem; Michelle M Mielke; Rosebud O Roberts; Bradley F Boeve; Ronald C Petersen Journal: Ann Neurol Date: 2013-02-19 Impact factor: 10.422
Authors: Eseosa T Ighodaro; Erin L Abner; David W Fardo; Ai-Ling Lin; Yuriko Katsumata; Frederick A Schmitt; Richard J Kryscio; Gregory A Jicha; Janna H Neltner; Sarah E Monsell; Walter A Kukull; Debra K Moser; Frank Appiah; Adam D Bachstetter; Linda J Van Eldik; Peter T Nelson Journal: J Cereb Blood Flow Metab Date: 2016-01-06 Impact factor: 6.200
Authors: Erin L Abner; Richard J Kryscio; Gregory E Cooper; David W Fardo; Gregory A Jicha; Marta S Mendiondo; Peter T Nelson; Charles D Smith; Linda J Van Eldik; Lijie Wan; Frederick A Schmitt Journal: Int J Alzheimers Dis Date: 2012-03-25
Authors: Omar M Al-Janabi; Christopher A Brown; Ahmed A Bahrani; Erin L Abner; Justin M Barber; Brian T Gold; Larry B Goldstein; Ronan R Murphy; Peter T Nelson; Nathan F Johnson; Leslie M Shaw; Charles D Smith; John Q Trojanowski; Donna M Wilcock; Gregory A Jicha Journal: J Alzheimers Dis Date: 2018 Impact factor: 4.472
Authors: David S Knopman; Samantha Budd Haeberlein; Maria C Carrillo; James A Hendrix; Geoff Kerchner; Richard Margolin; Paul Maruff; David S Miller; Gary Tong; Maria B Tome; Melissa E Murray; Peter T Nelson; Mary Sano; Niklas Mattsson; David L Sultzer; Thomas J Montine; Clifford R Jack; Hartmuth Kolb; Ronald C Petersen; Prashanthi Vemuri; Megan Zoschg Canniere; Julie A Schneider; Susan M Resnick; Gary Romano; Argonde Corien van Harten; David A Wolk; Lisa J Bain; Eric Siemers Journal: Alzheimers Dement Date: 2018-04 Impact factor: 21.566
Authors: Stephen D Ginsberg; Michael H Malek-Ahmadi; Melissa J Alldred; Yinghua Chen; Kewei Chen; Moses V Chao; Scott E Counts; Elliott J Mufson Journal: Neurobiol Dis Date: 2019-07-23 Impact factor: 5.996
Authors: Lilah M Besser; Charles Mock; Merilee A Teylan; Jason Hassenstab; Walter A Kukull; John F Crary Journal: J Neuropathol Exp Neurol Date: 2019-03-01 Impact factor: 3.685
Authors: Lilah M Besser; Walter A Kukull; Merilee A Teylan; Eileen H Bigio; Nigel J Cairns; Julia K Kofler; Thomas J Montine; Julie A Schneider; Peter T Nelson Journal: J Neuropathol Exp Neurol Date: 2018-08-01 Impact factor: 3.685
Authors: Peter T Nelson; Erin L Abner; Ela Patel; Sonya Anderson; Donna M Wilcock; Richard J Kryscio; Linda J Van Eldik; Gregory A Jicha; Zsombor Gal; Ruth S Nelson; Bela G Nelson; Jozsef Gal; Md Tofial Azam; David W Fardo; Matthew D Cykowski Journal: J Neuropathol Exp Neurol Date: 2018-01-01 Impact factor: 3.685
Authors: Lars Frings; Sabine Hellwig; Tobias Bormann; Timo S Spehl; Ralph Buchert; Philipp T Meyer Journal: Eur J Nucl Med Mol Imaging Date: 2018-03-15 Impact factor: 9.236
Authors: Erik S Musiek; Meghana Bhimasani; Margaret A Zangrilli; John C Morris; David M Holtzman; Yo-El S Ju Journal: JAMA Neurol Date: 2018-05-01 Impact factor: 18.302